Table 1.

Patient demographics and disease characteristics at baseline

Part 1: Phase IbPart 2: Phase II
Panitumumab + rilotumumab (AMG 102)Panitumumab + rilotumumab (AMG 102)Panitumumab + ganitumab (AMG 479)Panitumumab + placebo
(n = 11)(n = 48)(n = 46)(n = 48)
Men, n (%)5 (45)29 (60)25 (54)28 (58)
Age, mean years (range)56.5 (37–75)62.1 (45–78)62.0 (33–81)55.0 (19–75)
Age ≥ 65 years, n (%)4 (36)20 (42)18 (39)9 (19)
ECOG status, n (%)
 06 (55)24 (50)18 (39)15 (31)
 15 (45)23 (48)a28 (61)33 (69)
Metastatic sites, n (%)
 Liver only3 (27)5 (10)4 (9)5 (10)
 Liver + other sites5 (45)32 (67)29 (63)27 (56)
Prior line of therapy for mCRC, n (%)
 First-line therapy11 (100)48 (100)46 (100)46 (96)b
 Second-line therapy8 (73)33 (69)26 (57)31 (65)
 Third-line therapy and later3 (27)16 (33)12 (26)14 (29)
Prior therapies for mCRC, n (%)
 Oxaliplatin8 (73)42 (88)40 (87)39 (81)
 Irinotecan11 (100)32 (67)26 (57)30 (63)
 Oxaliplatin and irinotecan8 (73)26 (54)20 (44)23 (48)
 Bevacizumab5 (45)17 (35)12 (26)19 (40)
  • aOne patient with ECOG performance score of 2 was enrolled and was not counted as either ECOG performance score of 0 or 1; data from this patient were included in all efficacy and safety analyses.

  • bTwo patients had not received first-line therapy for mCRC; both patients had received oxaliplatin-based chemotherapy for non-mCRC in the adjuvant setting and progressed on therapy before entering the study.